GlassScriptPhysician profile
Andy Y Huang
NPI 1134150915
$26,671.97
in general payments reported to CMS, 2019-2025
21 companies · $2,395 in 2025
The $2,395 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,437 · 2020: $11K · 2021: $2,155 · 2022: $3,596 · 2023: $4,980 · 2024: $815 · 2025: $2,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,125 · Food and Beverage: $795 · Travel and Lodging: $253 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,125.00 |
| Food and Beverage | $794.50 |
| Travel and Lodging | $253.10 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $23,621.83 | 2019-2025 | Imfinzi, Tagrisso, Calquence |
| Beigene USA, INC. | $675.00 | 2024 | Brukinsa |
| Athenex Pharmaceutical Division, LLC | $521.72 | 2019 | |
| Novartis Pharmaceuticals Corporation | $280.53 | 2019-2024 | |
| Pfizer INC. | $265.62 | 2020-2025 | |
| Abbott Laboratories | $193.00 | 2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Janssen Biotech, INC. | $182.35 | 2020-2025 | Talvey, Tecvayli, Carvykti |
| Janssen Pharmaceuticals, INC | $149.62 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $141.47 | 2020-2025 | Opdivo |
| Lilly USA, LLC | $139.44 | 2019-2023 | Mounjaro |
| Amgen INC. | $98.78 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.58 | 2019-2025 | Ninlaro, Alunbrig |
| Astellas Pharma US INC | $73.95 | 2019 | |
| Merck Sharp & Dohme LLC | $59.88 | 2020-2024 | Keytruda |
| Array Biopharma INC | $39.15 | 2020-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $34.81 | 2022 | |
| Beone Medicines USA, INC. | $32.04 | 2025 | Brukinsa |
| Abbvie INC. | $24.67 | 2025 | |
| Eisai INC. | $21.57 | 2024 | |
| Incyte Corporation | $20.94 | 2019 | |
| Celgene Corporation | $19.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andy Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.